Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Screening for hereditary hemochromatosis?]

Pål Møller

    Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke
    |April 27, 2005
    PubMed
    Summary

    No abstract available in PubMed .

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Incidence Rates of Melanoma and Lung Cancer Are Generally Low in the Lynch Syndromes and Vary Across <i>path_MMR</i> Variants: A Prospective Lynch Syndrome Database Report.

    Cancers·2026
    Same author

    Risk of Breast Cancer After Ovarian Cancer in Women With a Pathogenic/Likely Pathogenic Variant in <i>BRCA1</i> or <i>BRCA2</i>.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
    Same author

    The Risk of Breast Cancer According to Mutation Type and Position in Carriers of a Pathogenic Variant in <i>BRCA1</i>.

    Current oncology (Toronto, Ont.)·2025
    Same author

    Menopausal hormone therapy and the risk of breast cancer in women with a pathogenic variant in BRCA1 or BRCA2.

    Journal of the National Cancer Institute·2025
    Same author

    Treatment of infertility and risk of breast cancer among women with a BRCA pathogenic variant: a matched case-control study.

    BMC cancer·2025
    Same author

    Ovarian cancer after breast cancer in women with a BRCA1 or BRCA2 pathogenic variant.

    Gynecologic oncology·2025